{
    "clinical_study": {
        "@rank": "158072", 
        "arm_group": [
            {
                "arm_group_label": "Sofosbuvir+ribavirin 16 weeks GT1", 
                "arm_group_type": "Experimental", 
                "description": "Participants with chronic genotype 1 HCV infection will receive sofosbuvir plus ribavirin for 16 weeks."
            }, 
            {
                "arm_group_label": "Sofosbuvir+ribavirin 24 weeks GT1", 
                "arm_group_type": "Experimental", 
                "description": "Participants with chronic genotype 1 HCV infection will receive sofosbuvir plus ribavirin for 24 weeks."
            }, 
            {
                "arm_group_label": "Sofosbuvir+ribavirin 16 weeks GT3", 
                "arm_group_type": "Experimental", 
                "description": "Participants with chronic genotype 3 HCV infection will receive sofosbuvir plus ribavirin for 16 weeks."
            }, 
            {
                "arm_group_label": "Sofosbuvir+ribavirin 24 weeks GT3", 
                "arm_group_type": "Experimental", 
                "description": "Participants with chronic genotype 3 HCV infection will receive sofosbuvir plus ribavirin for 24 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effectiveness and safety of sofosbuvir plus\n      ribavirin administered for 16 weeks and 24 weeks in patients with chronic genotype 1 (GT1)\n      or genotype 3 (GT3) HCV infection."
        }, 
        "brief_title": "Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed chronic genotype 1 or 3 HCV infection.\n\n          -  HCV treatment-na\u00efve.\n\n          -  Subjects will have cirrhosis status assessment; liver biopsy may be required.\n\n          -  Screening laboratory values within predefined thresholds.\n\n          -  Use of two effective contraception methods if female of childbearing potential or\n             sexually active male.\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing female or male with pregnant female partner.\n\n          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).\n\n          -  Contraindication to ribavirin therapy.\n\n          -  Excessive alcohol ingestion as defined by protocol.\n\n          -  History of solid organ transplantation.\n\n          -  Current or prior history of clinical hepatic decompensation.\n\n          -  History of clinically significant illness or any other medical disorder that may\n             interfere with subject treatment, assessment or compliance with the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896193", 
            "org_study_id": "GS-US-334-0119"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sofosbuvir+ribavirin 16 weeks GT1", 
                    "Sofosbuvir+ribavirin 24 weeks GT1", 
                    "Sofosbuvir+ribavirin 16 weeks GT3", 
                    "Sofosbuvir+ribavirin 24 weeks GT3"
                ], 
                "description": "Sofosbuvir 400 mg tablet administered orally once daily", 
                "intervention_name": "Sofosbuvir", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Sovaldi\u00ae", 
                    "PSI-7977", 
                    "GS-7977"
                ]
            }, 
            {
                "arm_group_label": [
                    "Sofosbuvir+ribavirin 16 weeks GT1", 
                    "Sofosbuvir+ribavirin 24 weeks GT1", 
                    "Sofosbuvir+ribavirin 16 weeks GT3", 
                    "Sofosbuvir+ribavirin 24 weeks GT3"
                ], 
                "description": "Ribavirin 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and \u2265 75 kg = 1200 mg)", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "RBV"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Institute of Nutrition of Academy of Sciences"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Institution of High Professional Education First Moscow State Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Central Scientific Research Institution of Gastroenterology of Moscow Healthcare Department"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Institution of Healthcare of Sverdlovsk Region"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "City Clinical Hospital 24"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Central Scientific and Research Institute of Epidemiology of Rospotrebnadzor"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Clinical Diagnostics and Research Center of Federal Bedgetary Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Krasnoyarsk Regional Center for Prevention and Control of AIDS and Infectious Diseases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Scientific Research Institution of Emergency Care n.a. N.V. Sclifosovskiy of Moscow"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Central Clinical Hospital of the Russian Academy of Sciences"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Institution of Tumen Region"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Stavropol State Medical University of Ministry of Healthcare"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Infectious Clinical Hospital No. 1"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint-Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Saint-Petersburg Center for Prevention and Control of AIDS and Infectious Diseases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint-Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Medical Military Academy n.a. S.M. Kirov"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Samara", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Medical Company Hepatolog"
                }
            }
        ], 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 3b, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Kathryn Kersey, MSc", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.", 
                "measure": "Proportion of participants with sustained virologic response 12 weeks after discontinuation of treatment (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Week 12"
            }, 
            {
                "measure": "Any adverse event leading to permanent discontinuation of study drug(s)", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896193"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "SVR4 and SVR24 is defined as HCV RNA < the lower limit of quantitation (LLOQ) 4 weeks and 24 weeks following the last dose of study drug, respectively.", 
                "measure": "Proportion of participants with sustained virologic response at 4 and 24 weeks after discontinuation of treatment (SVR4 and SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Weeks 4 and 24"
            }, 
            {
                "description": "On-treatment virologic failure is defined as either:\nBreakthrough: HCV RNA \u2265 LLOQ after having previously had HCV RNA < LLOQ, while on treatment, confirmed with 2 consecutive values (note: second confirmation value can be posttreatment), or last available on-treatment measurement with no subsequent follow-up values, OR\nRebound: > 1 log10IU/mL increase in HCV RNA from nadir while on treatment, confirmed with 2 consecutive values (note: second confirmation value can be posttreatment), or last available on-treatment measurement with no subsequent follow-up values, OR\nNonresponse: HCV RNA persistently \u2265 LLOQ through 8 weeks of treatment\nRelapse is defined as:\nHCV RNA \u2265 LLOQ during the posttreatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement", 
                "measure": "Proportion of participants with on-treatment virologic failure and relapse", 
                "safety_issue": "No", 
                "time_frame": "Baseline to posttreatment Week 24"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}